{"id":"tocilizumab-treatment","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Hypersensitivity reactions"},{"rate":"null","effect":"Liver enzyme elevations"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Interleukin-6 is a cytokine that plays a key role in the inflammatory response. By blocking the interleukin-6 receptor, tocilizumab reduces inflammation and prevents tissue damage. This mechanism is particularly useful in treating conditions characterized by excessive inflammation, such as rheumatoid arthritis.","oneSentence":"Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:13.201Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Juvenile idiopathic arthritis"},{"name":"Giant cell arteritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Systemic juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT04524871","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-11-01","conditions":"Advanced Liver Cancers","enrollment":518},{"nctId":"NCT07113743","phase":"PHASE1, PHASE2","title":"Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease","status":"ENROLLING_BY_INVITATION","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-09-10","conditions":"Chronic Granulomatous Disease (CGD)","enrollment":10},{"nctId":"NCT04729959","phase":"PHASE2","title":"Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-11","conditions":"Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma","enrollment":59},{"nctId":"NCT07477795","phase":"PHASE2","title":"Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04-01","conditions":"Takayasu Arteritis, Large Vessel Vasculitis","enrollment":52},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT07493317","phase":"PHASE2","title":"Neutralizing Interleukin (IL)-6","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03","conditions":"Major Depressive Disorder","enrollment":60},{"nctId":"NCT05233397","phase":"PHASE2","title":"ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-12-16","conditions":"Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma","enrollment":38},{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT02840175","phase":"PHASE3","title":"Treatment Tapering in JIA With Inactive Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-18","conditions":"Juvenile Idiopathic Arthritis","enrollment":62},{"nctId":"NCT07227597","phase":"PHASE1, PHASE2","title":"A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-29","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":170},{"nctId":"NCT05169515","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-26","conditions":"Non-Hodgkin Lymphoma","enrollment":121},{"nctId":"NCT04910568","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-07-26","conditions":"Multiple Myeloma","enrollment":126},{"nctId":"NCT04246086","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-12","conditions":"Follicular Lymphoma","enrollment":237},{"nctId":"NCT04634552","phase":"PHASE2","title":"A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hematological Malignancies","enrollment":510},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06934044","phase":"PHASE1","title":"A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-05-13","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT07467863","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC","enrollment":48},{"nctId":"NCT05835986","phase":"PHASE1","title":"A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-18","conditions":"Systemic Lupus Erythematosus","enrollment":70},{"nctId":"NCT03999749","phase":"PHASE2","title":"A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-06-11","conditions":"Melanoma","enrollment":71},{"nctId":"NCT07459335","phase":"","title":"TArget Trial Emulation Comparing Effectiveness of Tocilizumab vs Methotrexate In Corticosteroid-Treated GCA Patients","status":"COMPLETED","sponsor":"Groupe français d'étude des Maladies Inflammatoires de loeil","startDate":"2012-01-01","conditions":"Giant Cell Arteritis (GCA), Cardiovascular Diseases","enrollment":1667},{"nctId":"NCT05583617","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-11-14","conditions":"Multiple Myeloma","enrollment":200},{"nctId":"NCT04940299","phase":"PHASE2","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-23","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma","enrollment":35},{"nctId":"NCT05927571","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-08-10","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":120},{"nctId":"NCT03075696","phase":"PHASE1, PHASE2","title":"A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-02-21","conditions":"Non-Hodgkin's Lymphoma","enrollment":940},{"nctId":"NCT05207670","phase":"PHASE2","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-02-01","conditions":"Non-Hodgkin Lymphoma","enrollment":320},{"nctId":"NCT07115745","phase":"PHASE1","title":"A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-09-04","conditions":"Refractory Autoimmune Diseases","enrollment":125},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT05091424","phase":"PHASE1","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-07","conditions":"Chronic Lymphocytic Leukemia","enrollment":137},{"nctId":"NCT04077723","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-08-13","conditions":"Lymphoma, Non-Hodgkin","enrollment":498},{"nctId":"NCT07108387","phase":"PHASE2","title":"Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-12-11","conditions":"Giant Cell Arteritis (GCA)","enrollment":78},{"nctId":"NCT05972135","phase":"PHASE2","title":"Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma","status":"RECRUITING","sponsor":"SCRI Development Innovations, LLC","startDate":"2023-10-23","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT04980222","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-22","conditions":"Lymphoma","enrollment":46},{"nctId":"NCT03970226","phase":"EARLY_PHASE1","title":"Tocilizumab in Children With ACP","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2019-09-16","conditions":"Adamantinomatous Craniopharyngioma","enrollment":9},{"nctId":"NCT07392814","phase":"PHASE1","title":"Study With Tocilizumab in Combination With Venetoclax and Azacitidine Chemotherapy in Patients With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-03-10","conditions":"Leukemia Acute Myeloid - AML","enrollment":12},{"nctId":"NCT05646836","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-03-21","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT05391750","phase":"PHASE1","title":"Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-10-19","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":7},{"nctId":"NCT07006532","phase":"NA","title":"Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab","status":"RECRUITING","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2025-01-01","conditions":"Kidney Transplant Rejection","enrollment":50},{"nctId":"NCT04412772","phase":"PHASE3","title":"Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS","status":"TERMINATED","sponsor":"Queen's Medical Center","startDate":"2020-06-12","conditions":"COVID-19","enrollment":20},{"nctId":"NCT05535244","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-17","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT05734690","phase":"PHASE4","title":"COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2023-05-05","conditions":"Heart Failure","enrollment":503},{"nctId":"NCT03275103","phase":"PHASE1","title":"Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2017-09-19","conditions":"Multiple Myeloma","enrollment":355},{"nctId":"NCT04712097","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-27","conditions":"Relapsed or Refractory Follicular Lymphoma","enrollment":478},{"nctId":"NCT07377058","phase":"NA","title":"RCT of Tocilizumab for Anti-MDA5+DM","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-11-01","conditions":"Dermatomyositis","enrollment":110},{"nctId":"NCT06492837","phase":"PHASE2","title":"Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2024-10-23","conditions":"Follicular Lymphoma","enrollment":56},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT06381661","phase":"PHASE2","title":"Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-05-01","conditions":"Sepsis","enrollment":2000},{"nctId":"NCT03869190","phase":"PHASE1, PHASE2","title":"Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-06-01","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":272},{"nctId":"NCT05070247","phase":"PHASE1, PHASE2","title":"A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors","status":"TERMINATED","sponsor":"Takeda","startDate":"2022-04-14","conditions":"Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma","enrollment":61},{"nctId":"NCT05846789","phase":"PHASE2","title":"SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers","status":"RECRUITING","sponsor":"Kathy Miller","startDate":"2024-07-02","conditions":"Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer","enrollment":168},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT01782235","phase":"PHASE2, PHASE3","title":"Efficacy of Tocilizumab in Primary Sjögren's Syndrome.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2013-07-24","conditions":"Primary Sjögren's Syndrome (pSS)","enrollment":110},{"nctId":"NCT07254637","phase":"PHASE2","title":"Tocilizumab in Chronic Inflammatory CPPD Disease","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04","conditions":"Calcium Pyrophosphate Deposition Disease","enrollment":80},{"nctId":"NCT05869955","phase":"PHASE1","title":"A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2023-09-13","conditions":"Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis","enrollment":270},{"nctId":"NCT07334379","phase":"PHASE2","title":"Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study","status":"RECRUITING","sponsor":"Lorenzo delSorbo","startDate":"2025-10-20","conditions":"Acute Hypoxemic Respiratory Failure","enrollment":60},{"nctId":"NCT06037460","phase":"PHASE3","title":"TocilizuMab discontinuAtion in GIant Cell Arteritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2024-05-13","conditions":"Giant Cell Arteritis","enrollment":120},{"nctId":"NCT06043674","phase":"PHASE2","title":"Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2024-01-22","conditions":"Chronic Lymphocytic Leukemia, Richter's Transformation","enrollment":70},{"nctId":"NCT04408638","phase":"PHASE3","title":"A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-02-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":270},{"nctId":"NCT04691817","phase":"PHASE1, PHASE2","title":"Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy","status":"RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2023-07-25","conditions":"Lung Cancer, Nonsmall Cell","enrollment":28},{"nctId":"NCT04616248","phase":"PHASE1","title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-01-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":14},{"nctId":"NCT04395222","phase":"PHASE2","title":"Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-07","conditions":"Hematologic Malignancy, Bone Marrow Transplant","enrollment":21},{"nctId":"NCT03533283","phase":"PHASE1, PHASE2","title":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-05-08","conditions":"Non-Hodgkins Lymphoma","enrollment":211},{"nctId":"NCT07281027","phase":"PHASE3","title":"COMparison Between Anakinra and Tocilizumab in NORSE - \"COMBAT-NORSE\"","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03-01","conditions":"New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)","enrollment":438},{"nctId":"NCT03337698","phase":"PHASE1, PHASE2","title":"A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-27","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":314},{"nctId":"NCT07263776","phase":"PHASE3","title":"Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2","status":"RECRUITING","sponsor":"Capital Medical University","startDate":"2025-12-05","conditions":"Acute Ischemic Stroke","enrollment":692},{"nctId":"NCT06251076","phase":"PHASE4","title":"Plan Development for Giving Teclistamab in the Outpatient Setting","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-11-19","conditions":"Multiple Myeloma, Relapsed Cancer, Refractory Cancer","enrollment":15},{"nctId":"NCT07080125","phase":"","title":"A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-06-17","conditions":"Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease","enrollment":2000},{"nctId":"NCT03564340","phase":"PHASE1, PHASE2","title":"Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-05-21","conditions":"Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer","enrollment":890},{"nctId":"NCT05364424","phase":"PHASE1","title":"A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-11-04","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":43},{"nctId":"NCT03892785","phase":"PHASE3","title":"MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2020-01-27","conditions":"Giant Cell Arteritis","enrollment":230},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT03651518","phase":"PHASE2","title":"Personalized Therapies in Inflammatory Complex Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-20","conditions":"Inflammatory Disease, Autoimmune Diseases","enrollment":32},{"nctId":"NCT03787290","phase":"PHASE2","title":"Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder","status":"SUSPENDED","sponsor":"Massachusetts General Hospital","startDate":"2026-12-01","conditions":"Major Depressive Disorder","enrollment":35},{"nctId":"NCT06262477","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2024-01-02","conditions":"Healthy Volunteer","enrollment":300},{"nctId":"NCT01791842","phase":"PHASE2","title":"TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-05-05","conditions":"Fibrous Dysplasia of Bone","enrollment":19},{"nctId":"NCT01673919","phase":"PHASE3","title":"A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02","conditions":"Juvenile Idiopathic Arthritis","enrollment":7},{"nctId":"NCT05237232","phase":"","title":"Modeling of Intracerebral Vascularization After Extracorporeal Membrane Oxygenation in Children","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-03-31","conditions":"Extra Corporeal Membrane Oxygenation, Decanulated Alive","enrollment":30},{"nctId":"NCT01394276","phase":"","title":"An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":322},{"nctId":"NCT04007029","phase":"PHASE1","title":"Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-10-04","conditions":"CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT03677154","phase":"PHASE1, PHASE2","title":"Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-05-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":188},{"nctId":"NCT07106671","phase":"PHASE2","title":"A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-10","conditions":"CRS - Cytokine Release Syndrome, Myeloma","enrollment":20},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT06488521","phase":"PHASE1","title":"A Safety and Pharmacokinetics Study of Complarate (Tocilizumab Biosimilar Solution) and Actemra® in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"AO GENERIUM","startDate":"2024-06-20","conditions":"Healthy Volunteers","enrollment":256},{"nctId":"NCT04692493","phase":"PHASE3","title":"RA-PRO PRAGMATIC TRIAL","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Rheumatoid Arthritis","enrollment":924},{"nctId":"NCT07052058","phase":"PHASE2","title":"Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2025-08-25","conditions":"Treatment-Resistant Major Depressive Disorder","enrollment":32},{"nctId":"NCT04888221","phase":"PHASE3","title":"Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-24","conditions":"Giant Cell Arteritis, Neurovascular Disorder","enrollment":66},{"nctId":"NCT05168475","phase":"PHASE2","title":"Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-07-14","conditions":"Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome","enrollment":22},{"nctId":"NCT05394909","phase":"","title":"Ultra-short Glucocorticosteroids and Tocilizumab Therapy in GCA Patients","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2020-02-07","conditions":"GCA, TOCILIZUMAB, Glucocorticoids","enrollment":20},{"nctId":"NCT04331808","phase":"PHASE2","title":"CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-03-30","conditions":"Corona Virus Infection","enrollment":228},{"nctId":"NCT04479358","phase":"PHASE2","title":"Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19","status":"TERMINATED","sponsor":"University of Chicago","startDate":"2020-09-10","conditions":"COVID-19","enrollment":85},{"nctId":"NCT06016179","phase":"PHASE1","title":"Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer","status":"RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2024-01-30","conditions":"Malignant Pleural Effusion, Malignant Ascites","enrollment":12},{"nctId":"NCT03821246","phase":"PHASE2","title":"Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy","status":"RECRUITING","sponsor":"David Oh","startDate":"2019-10-30","conditions":"Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer","enrollment":68},{"nctId":"NCT04363853","phase":"PHASE2","title":"Tocilizumab Treatment in Patients With COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2020-06-01","conditions":"Sars-CoV2","enrollment":200},{"nctId":"NCT05067348","phase":"PHASE2","title":"Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2022-07-21","conditions":"Myasthenia Gravis, Generalized","enrollment":64},{"nctId":"NCT03859388","phase":"","title":"Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-03-01","conditions":"Rejection Chronic Renal, Kidney Transplant Rejection","enrollment":10},{"nctId":"NCT03434730","phase":"PHASE2","title":"Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-02-07","conditions":"Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia","enrollment":46},{"nctId":"NCT06927375","phase":"PHASE4","title":"A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy","status":"RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2024-12-12","conditions":"Thyroid-Associated Ophthalmopathy","enrollment":60},{"nctId":"NCT06624436","phase":"PHASE4","title":"Immunomodulatory Effects of Dexamethasone, Tocilizumab and Anakinra During Experimental Human Endotoxemia","status":"RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2024-10-24","conditions":"Sepsis, Neuroinflammatory Response, Immunosuppresion","enrollment":52},{"nctId":"NCT04561986","phase":"PHASE3","title":"TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2022-02-01","conditions":"Antibody-mediated Rejection","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":500,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tocilizumab treatment","genericName":"Tocilizumab treatment","companyName":"Centre Hospitalier Universitaire Dijon","companyId":"centre-hospitalier-universitaire-dijon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tocilizumab is a monoclonal antibody that inhibits the interleukin-6 receptor alpha subunit, used to treat conditions such as Rheumatoid Arthritis, Multiple Myeloma, Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica, and Devic's Disease. It is classified as an interleukin-6 receptor alpha subunit inhibitor and has been studied in combination with other treatments, including Methotrexate and Cevostamab, in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}